Alpha-Lipoic Acid Side Effects: GI Upset, Hypoglycemia & IAS
Informational summary of published research — not medical advice. ALA can lower blood sugar; if you take insulin or a sulfonylurea, or have unexplained hypoglycemia symptoms, talk to a doctor before starting or continuing it.
At the standard 600–800 mg/day oral dose, ALA is well tolerated. Mild nausea and stomach upset are the most common complaints, and controlled trials found adverse-event rates similar to placebo. A less common but distinctive quirk is a sulfurous, rotten-egg smell to burps — harmless, just surprising. Two things matter more than the GI upset. First, ALA itself lowers blood glucose, and because most people take it for diabetic neuropathy, the overlap with insulin or diabetes medication is the norm, not the exception — that combination can add up to hypoglycemia. Second, there's a rare but real reaction called insulin autoimmune syndrome (Hirata disease), tied to a specific genetic predisposition and documented mainly in Japan with a small number of European case reports since. It's genuinely uncommon, not a general population risk, but worth knowing by name if you develop unexplained low blood sugar.
Looking for a tested product? See our best alpha-lipoic acid ranked by cost per 100mg of active R, which also links back to this safety detail →
Day-to-day tolerability: mild GI upset, and a smell that surprises people
Across the oral trials behind ALA's diabetic-neuropathy evidence, the compound has a consistent reputation: well tolerated. The DEKAN trial, an 800 mg/day oral dose for four months, reported no difference between ALA and placebo in the rates of adverse events (Ziegler 1997, PMID: 9051389). The 2024 Cochrane review pooling three long-term trials (1,090 participants) found little or no difference between ALA and placebo in adverse events leading to treatment discontinuation within six months (Baicus 2024, PMID: 38205823). None of that means side effects are zero — the complaints that do come up are mostly mild nausea, stomach discomfort, or heartburn, more likely early in use or with a larger single dose rather than a split one.
A second, more distinctive complaint isn't captured well in trial adverse-event tables at all: a sulfurous, faintly rotten-egg smell to burps, which some people notice within the first days of use. It follows directly from ALA's chemical structure — a five-membered ring built around a pair of sulfur atoms — and it's harmless, just unexpected if nobody warns you about it. If GI upset does bother you, taking ALA with food reduces it, though that comes at a real cost to absorption; see our dosage guide for the usual empty-stomach timing and the trade-off.
The safety issue that actually matters: hypoglycemia with diabetes medication
ALA lowers blood glucose on its own — and most people taking it are already on a glucose-lowering drug. A meta-analysis of 24 randomized trials found ALA significantly reduced fasting glucose and HbA1c in people with metabolic disease (Akbari 2018, PMID: 29990473). That's a modest effect on its own, but ALA's strongest use case is diabetic peripheral neuropathy, so the people reaching for it are disproportionately already managing diabetes with insulin or an oral medication. Layering ALA's own glucose-lowering effect on top of insulin or a sulfonylurea (glipizide, glimepiride, glyburide) can add up to hypoglycemia — not a rare drug-interaction edge case here, but the default scenario for this supplement's typical user.
This is a mechanism-based caution rather than a dedicated interaction trial, but it's a real one: if you take insulin or a sulfonylurea, monitor your blood sugar more closely when starting ALA and coordinate any dose changes with your doctor rather than adjusting on your own.
Insulin autoimmune syndrome (Hirata disease): rare, but worth knowing by name
This is the side effect that gets the most attention relative to how often it actually happens, so it's worth being precise. Insulin autoimmune syndrome (IAS), also called Hirata disease, is a condition where the body produces antibodies against its own insulin, causing spontaneous hypoglycemia with unusually high measured insulin levels. It was first linked to ALA in Japan — an early case report described the association in a Japanese patient (Ishida 2007, PMID: 17586737) — and a strong genetic predisposition underlies it: the HLA-DRB1*04:06 variant in Japanese patients, and a related but distinct variant, HLA-DRB1*04:03, in the small number of European cases reported since. One Italian case series described six Caucasian patients who developed IAS after taking 600 mg/day of ALA, five carrying HLA-DRB1*04:03 and one carrying HLA-DRB1*04:06 (Gullo 2014, PMID: 24111525); a second report described two more European cases, both HLA-DRB1*04:03 (Moffa 2019, PMID: 30086435).
Those are case reports, not a population-level risk estimate — eight documented European cases is not the same as "this happens to European ALA users." For the actual population picture, Europe's food safety authority reviewed the published evidence, including 49 case reports of ALA-associated IAS in total, and found that symptoms resolved within weeks to months once ALA was stopped in every case reviewed. Separately, it cites an estimate that the overall incidence of IAS in Japan (from any cause, not ALA specifically) was about 0.017 cases per 100,000 people in 2017–2018, and states that Europe's incidence is likely even lower — while also concluding that the specific risk attributable to ALA "cannot be quantified precisely" from the available data (EFSA Panel on Nutrition 2021, PMID: 34122657). Put plainly: this is a genuinely rare reaction with a real biological mechanism and a known genetic risk group, not a common outcome you should expect. If you develop unexplained hypoglycemia while taking ALA — shakiness, confusion, sweating, without a clear cause — stop taking it and see a clinician; the condition is treatable and typically resolves once ALA is discontinued.
Two more interactions worth knowing: biotin and thiamine
- Biotin (shared transporter, not demonstrated deficiency). Researchers identified the transporter that carries the active R-(+) form of ALA into cells — the human Na+/multivitamin transporter, hSMVT — which is the same transporter known to carry biotin and pantothenic acid (Zehnpfennig 2015, PMID: 25971966). That's a mechanistic finding from a cell/transporter-based study, not a clinical trial showing ALA supplementation causes biotin deficiency in people. It's a reasonable reason not to stack a high-dose biotin supplement with high-dose ALA at the exact same time, not a reason to avoid the combination altogether.
- Thiamine (correct any deficiency first). ALA and thiamine (vitamin B1) both function in the same metabolic pathway, the pyruvate dehydrogenase complex. Standard clinical guidance — most relevant for people with poor nutrition or heavy alcohol use, where thiamine deficiency is more likely — is to identify and correct thiamine deficiency before or alongside starting ALA rather than layering it on top of an unaddressed deficiency. This is a mechanism-based precaution we did not find quantified in a dedicated human trial, so treat it as sensible practice rather than a documented risk with a number attached.
Alpha-lipoic acid side effects at a glance
| Effect | How common per our sources | What to do | When it matters |
|---|---|---|---|
| GI upset (nausea, stomach discomfort) | Reported, but not significantly more than placebo in controlled trials at 600–800mg/day | Split the dose or take with food if needed; ramp up gradually | Always — the default early-use complaint |
| Sulfurous odor to burps/breath | Widely reported anecdotally; not systematically quantified in trial data | No action needed — harmless | Cosmetic only, tends to fade with continued use |
| Hypoglycemia (added to insulin/sulfonylureas) | Mechanism-based: ALA measurably lowers glucose on its own | Monitor blood sugar closely; coordinate with your clinician | Common overlap — most ALA users are already on diabetes medication |
| Insulin autoimmune syndrome (Hirata disease) | Rare: 49 case reports reviewed by EFSA; Japan's overall IAS incidence ~0.017/100,000 (2017–18) | Stop ALA and see a clinician if unexplained hypoglycemia develops; resolves after discontinuation | Genuinely rare, but the one reaction worth knowing by name |
| Biotin transporter competition | Lab/mechanistic finding only (shared hSMVT transporter) | Avoid mega-dosing biotin and ALA at the exact same time if being cautious | Theoretical — not shown to cause biotin deficiency in people |
| Thiamine depletion risk | Mechanism-based caution (shared metabolic pathway); no dedicated trial data | Correct any known thiamine deficiency before/while starting ALA | Mainly relevant with poor nutrition or heavy alcohol use |
Compare Alpha-Lipoic Acid Products by Cost Per Active R
If you're ready to buy, here's how the alpha-lipoic acid products we track and verify compare on cost per 100mg of active R.
Frequently asked questions
What are the most common alpha-lipoic acid side effects?
Mild gastrointestinal upset — nausea, stomach discomfort, or heartburn — is what most people notice, especially when starting out or taking a larger single dose. In controlled trials at the standard 600-800mg/day oral dose, rates of adverse events were not significantly different from placebo, and treatment was described as well tolerated. A second, more distinctive but harmless complaint some people report is a sulfurous, faintly rotten-egg smell to their burps, which follows from ALA's sulfur-containing chemical structure. Neither is dangerous, and both tend to be more noticeable early on.
Can alpha-lipoic acid cause low blood sugar (hypoglycemia)?
Yes, and this matters more than the GI upset for most people who actually take ALA. ALA itself measurably lowers blood glucose — a meta-analysis of 24 trials found it significantly reduced fasting glucose and HbA1c in people with metabolic disease. Because ALA's best-evidenced use is diabetic neuropathy, most people taking it are already on insulin or a diabetes medication, so the combination isn't an edge case, it's the norm. Stacking ALA on top of insulin or a sulfonylurea (glipizide, glimepiride, glyburide) can add up to hypoglycemia. If you take one of those medications, monitor your blood sugar and talk to your doctor before adding ALA.
What is insulin autoimmune syndrome, and how worried should I be about it?
It's a rare condition, sometimes called Hirata disease, in which the body makes antibodies against its own insulin, causing spontaneous hypoglycemia. It was first linked to alpha-lipoic acid in Japan, and a strong genetic predisposition is involved — mainly the HLA-DRB1*04:06 gene variant in Japanese patients and HLA-DRB1*04:03 in the small number of European cases reported since (eight total across two case series). Population-level data from Europe's food safety authority, reviewing 49 case reports overall, describes it as genuinely rare and states the precise risk from ALA specifically can't be quantified from available data — this is not a common reaction. Symptoms resolve within weeks to months of stopping ALA. If you develop unexplained hypoglycemia while taking it, stop and see a clinician.
Does alpha-lipoic acid interact with biotin or thiamine?
Two lower-profile points worth knowing. First, lab research identified the transporter that carries R-lipoic acid into cells (hSMVT) as the same one that carries biotin and pantothenic acid, so there's a plausible, mechanism-based reason not to take a very high dose of biotin at the exact same time as ALA — this hasn't been shown to cause biotin deficiency in people at normal doses. Second, ALA and thiamine (vitamin B1) work in the same metabolic pathway (the pyruvate dehydrogenase complex), which is the basis for standard clinical guidance to correct any existing thiamine deficiency — most relevant in people with poor nutrition or heavy alcohol use — before or alongside starting ALA, rather than adding it on top of an unaddressed deficiency.
Related guides
- Does Alpha-Lipoic Acid Work? — the full route-by-route evidence table, plus the hypoglycemia and IAS cautions in context of what ALA actually does
- Alpha-Lipoic Acid Benefits — the evidence-graded map of every claimed benefit, tier by tier
- R vs Racemic Alpha-Lipoic Acid — why only R is active, and why racemic is still the cheaper source
- Alpha-Lipoic Acid Dosage Guide — the 600mg/day protocol and empty-stomach timing
- Best Alpha-Lipoic Acid Supplement — verified picks, ranked by cost per active R
- All Alpha-Lipoic Acid Guides
Sources
- Ziegler D, et al. "Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study)." Diabetes Care. 1997;20(3):369-373. PMID: 9051389 (oral 800mg/day × 4 months; no difference in adverse event rates vs. placebo).
- Baicus C, et al. "Alpha-lipoic acid for diabetic peripheral neuropathy." Cochrane Database Syst Rev. 2024. PMID: 38205823 (3 trials, 1,090 participants; little or no difference in adverse events leading to cessation within 6 months, RR 1.48, 95% CI 0.50–4.35).
- Akbari M, et al. "The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis." Metabolism. 2018;87:56-69. PMID: 29990473 (24 RCTs; significant reduction in fasting glucose and HbA1c).
- Ishida Y, et al. "Alpha-lipoic acid and insulin autoimmune syndrome." Diabetes Care. 2007;30(9):2240-2241. PMID: 17586737 (early case report from Japan linking ALA to IAS).
- Gullo D, et al. "Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking alpha-lipoic acid." Clin Endocrinol (Oxf). 2014;81(2):204-209. PMID: 24111525 (6 Caucasian cases, 600mg/day; HLA-DRB1*04:03 in 5, HLA-DRB1*04:06 in 1).
- Moffa S, et al. "Potential cause-effect relationship between insulin autoimmune syndrome and alpha lipoic acid: Two case reports." Nutrition. 2019;57:1-4. PMID: 30086435 (2 further European cases, both HLA-DRB1*04:03).
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). "Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome." EFSA J. 2021;19(6):e06577. PMID: 34122657 (review of 49 case reports; symptoms resolved after discontinuation in all cases reviewed; Japan's overall IAS incidence estimated ~0.017/100,000 in 2017-2018; ALA-specific risk "cannot be quantified precisely").
- Zehnpfennig B, et al. "Interaction of alpha-Lipoic Acid with the Human Na+/Multivitamin Transporter (hSMVT)." J Biol Chem. 2015;290(26):16372-16382. PMID: 25971966 (identifies R-lipoic acid as an hSMVT substrate; hSMVT also transports biotin and pantothenic acid).